Trial Profile

Phase 2b open label extension clinical study of enobosarm to prevent muscle loss

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 23 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enobosarm (Primary)
Indications Muscular atrophy; Obesity; Overweight
Focus Therapeutic Use

Most Recent Events

21 Oct 2024 According to a Veru media release, the Company will present Meta-analysis of subjects from 4 randomized clinical trials supports the potential of enobosarm to optimize weight loss, at ObesityWeek, taking place November 3-6, 2024, in San Antonio, Texas.
02 May 2024 According to a Veru media release, topline results of the separate blinded Phase 2b extension clinical study are expected in calendar Q2 2025.
25 Apr 2024 According to Veru media release, data from this trial will be presented at at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting, taking place May 9-11, 2024 in New Orleans, LA.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com